AI Article Synopsis
- Duchenne muscle dystrophy (DMD) causes muscle damage and respiratory failure due to the absence of dystrophin, with inflammation playing a harmful role in the disease progression.
- Previous research showed that short-term treatment with eicosapentaenoic acid (EPA) improved DMD in early stages in mdx mice, a model for DMD.
- This study examines the effects of long-term omega-3 therapy, which enhanced muscle regeneration and reduced inflammation markers, suggesting it could be a viable treatment for later stages of DMD in clinical trials.
Article Abstract
In Duchenne muscle dystrophy (DMD) and in the mdx mouse model of DMD, a lack of dystrophin leads to myonecrosis and cardiorespiratory failure. Several lines of evidence suggest a detrimental role of the inflammatory process in the dystrophic process. Previously, we demonstrated that short-term therapy with eicosapentaenoic acid (EPA), at early stages of disease, ameliorated dystrophy progression in the mdx mouse. In the present study, we evaluated the effects of a long-term therapy with omega-3 later in dystrophy progression. Three-month-old mdx mice received omega-3 (300 mg/kg) or vehicle by gavage for 5 months. The quadriceps and diaphragm muscles were removed and processed for histopathology and Western blot. Long-term therapy with omega-3 increased the regulatory protein MyoD and muscle regeneration and reduced markers of inflammation (TNF-α and NF-kB) in both muscles studied. The present study supports the long-term use of omega-3 at later stages of dystrophy as a promising option to be investigated in DMD clinical trials.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ar.23177 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!